['TABLE 4 DRUGS TESTED IN IN VITRO BINDING OR IN VIVO DRUG INTERACTION TESTING OR WITH POST-MARKETING REPORTS', 'A SHOULD BE ADMINISTERED AT LEAST 4 HOURS PRIOR TO WELCHOL', 'B NO SIGNIFICANT ALTERATION OF WARFARIN DRUG LEVELS WITH WARFARIN AND WELCHOL COADMINISTRATION IN AN IN VIVO STUDY WHICH DID NOT EVALUATE WARFARIN PHARMACODYNAMICS (INR). [SEE POST-MARKETING EXPERIENCE (6.2) ]', 'C CYCLOSPORINE LEVELS SHOULD BE MONITORED AND, BASED ON THEORETICAL GROUNDS, CYCLOSPORINE SHOULD BE ADMINISTERED AT LEAST 4 HOURS PRIOR TO WELCHOL.', 'DRUGS WITH A KNOWN INTERACTION WITH COLESEVELAM', 'CYCLOSPORINE C , GLYBURIDE A , LEVOTHYROXINE A , AND ORAL CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL AND NORETHINDRONE A', 'DRUGS WITH POSTMARKETING REPORTS CONSISTENT WITH POTENTIAL DRUG-DRUG INTERACTIONS WHEN COADMINISTERED WITH WELCHOL', 'PHENYTOIN A , WARFARIN B', 'DRUGS THAT DO NOT INTERACT WITH COLESEVELAM BASED ON IN VITRO OR IN VIVO TESTING', 'CEPHALEXIN, CIPROFLOXACIN, DIGOXIN, WARFARIN B FENOFIBRATE, LOVASTATIN, METFORMIN, METOPROLOL, PIOGLITAZONE, QUINIDINE, REPAGLINIDE, VALPROIC ACID, VERAPAMIL']